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Smear microscopy for acid-fast bacilli (AFB) is the standard tool for the diagnosis of pulmonary tu-
berculosis (TB) caused by Mycobacterium tuberculosis in 
Fiji. Sputum culture using Ogawa medium is used to 
complement AFB smear microscopy, especially among 
smear-negative specimens. Diagnosis of TB in Fiji is 
constrained by the low sensitivity of AFB smear mi-
croscopy, the inability to determine drug susceptibility 
and the variability in operator performance. In addi-
tion, solid culture takes about 6–8 weeks to obtain a 
result, and significant numbers of cultures become 
contaminated.
In June 2012, the Fiji National TB Programme in-
troduced the Xpert® MTB/RIF assay (Cepheid, Sunny-
vale, CA, USA) at the three anti-tuberculosis treatment 
centres in Fiji to increase case detection rates and in-
vestigate rifampicin (RMP) resistance. Xpert is a car-
tridge-based, fully automated, real-time nucleic acid 
amplification test for rapid detection of M. tuberculosis 
and RMP resistance, which is a good marker for multi-
drug-resistant TB (MDR-TB). Results are obtained 
within 2 h, which helps reduce the length of hospital-
isation and the number of deaths due to TB.1 The re-
sults from a recent study showed that the mean time 
to TB detection was 1 day for Xpert, whereas smear 
microscopy requires a day.2
A number of issues have been identified while im-
plementing Xpert in Fiji, and this requires further in-
vestigation. These included a significant number of er-
rors during sample testing and issues related to the 
short shelf-life of the kits. Similar issues were identi-
fied by the World Health Organization in 2011.2 Fiji 
now has three diagnostic tools for TB, with a degree of 
overlap in their functionality. There is therefore a 
need to understand the diagnostic value of Xpert and 
its level of agreement with AFB smear microscopy and 
TB culture in Fiji. It was also important to compare 
the performance of the three TB treatment centres and 
the quality of sputum to determine if these had con-
tributed to the errors. We therefore conducted this 
study to provide answers to some of these questions 
and to prevent the previously mentioned constraints 
from recurring.
METHODS
This was a retrospective study using data from all sam-
ples tested with Xpert in the three anti-tuberculosis 
treatment centres in Fiji from June 2012 to February 
2013.
Setting
Fiji is an archipelago of more than 322 islands which 
lies at the heart of the Pacific Ocean. The population 
of Fiji is approximately 837 271,3 87% of whom reside 
in the two major islands, Viti Levu and Vanua Levu. 
There are three anti-tuberculosis treatment centres 
and four AFB smear microscopy laboratories in Fiji. 
Tuberculosis culture on Ogawa medium is only per-
formed by the Daulako Mycobacterium Reference Lab-
oratory (DMRL), located in P J Twomey Hospital in the 
capital, Suva. Xpert testing is performed at the DMRL, 
Lautoka and Labasa Hospitals. The National Tubercu-
losis Programme (NTP) criteria for the use of Xpert in-
clude patients who are symptomatic but AFB 
smear-negative (on three specimens), AFB smear-posi-
tive but failed to convert after 3 months of the inten-
sive phase of treatment, relapses after apparently suc-
cessful treatment, human immunodeficiency virus 
(HIV) positive patients and cases from high multi-
drug-resistant TB burden countries.
Data variables, data collection instrument
Data for Xpert testing performed between June 2012 
and February 2013 were extracted from the AFB smear 
microscopy register in the laboratories in each of the 
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Setting: All Xpert® MTB/RIF tests performed in the three 
TB (tuberculosis) treatment centres in Fiji from June 2012 
to February 2013.
Objectives: To determine 1) the number of Xpert tests 
performed in each centre, 2) the association between 
sputum quality and Xpert results, 3) the agreement of 
Xpert with acid-fast bacilli (AFB) smear microscopy and 
TB culture and 4) error rates.
Design: Retrospective review of records.
Results: A total of 415 Xpert tests were performed in the 
study period. Mycobacterium tuberculosis was detected in 
69 (16.6%) samples. No rifampicin resistance was de-
tected. M. tuberculosis was detected from 60 (18.7%) 
good-quality sputum samples. A total of 43 (10.4%) er-
rors occurred during this period. M. tuberculosis was de-
tected in 10 (2.9%) smear-negative specimens. There 
was a substantial and an almost perfect agreement be-
tween Xpert and AFB microscopy (κ = 0.793) and culture 
results (κ = 0.818), respectively.
Conclusion: Although a good correlation between Xpert 
and the two tests were shown in the study, Xpert should 
not replace the routine first-line TB diagnostic tests used 
in Fiji for reasons related to logistics and sustainability. A 
further evaluation of the assay’s performance is required 
over a longer time period to gauge its diagnostic value in 
detecting smear-negative, Xpert-positive cases in Fiji.
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three anti-tuberculosis treatment centres. Data for each 
variable were manually collected into a structured pro-
forma. Exposure variables for each sputum specimen 
included quality of sputum (poor or good), age, sex and 
testing laboratory. Quality of sputum was classified as 
follows: good = blood-stained, mucoid or purulent; 
poor = thin, watery or mainly composed of bubbles and 
saliva. Outcome variables included Xpert, smear and 
culture results. AFB smear microscopy results were clas-
sified according to the International Union for Tuber-
culosis and Lung Disease (The Union), Paris, France.4
Analysis and statistics
Data were collected manually and double-entered into 
an electronic database (EpiData, version 3.1, EpiData 
Association, Odense, Denmark). A uniform data entry 
file was developed using EpiData Entry 3.1. Errors in 
data entry were detected by comparing the duplicate 
EpiData files for any discordance. Corrections were 
made by cross-checking with the proformas to produce 
a final data set.
Data were first analysed using descriptive explor-
atory statistics. The statistical significance of observed 
differences between the proportions of determinants 
and outcome variables was determined using the χ2 test 
at a 95% confidence level using EpiAnalysis (EpiData 
Association). The level of agreement between tests (κ), 
sensitivity and specificity and their binomial 95% con-
fidence intervals (CIs) for Xpert using culture and AFB 
smear microscopy, were calculated using WinEpi.5
Ethics approval
Ethics approval was obtained from the Ethics Advisory 
Group (EAG) of The Union, the National Health Re-
search Committee, Suva, and the Fiji National Re-
search Ethics Review Committee, Suva, Fiji.
RESULTS
The results from testing 415 sputum specimens using 
Xpert are presented in Table 1. The majority of the 
samples were tested at the DMRL (n = 164, 39.5%), fol-
lowed by the Western (n = 114, 27.5%) and Northern 
Divisions (n = 137, 33.0%).
Sputum quality
A total of 94 (22.7%) sputum specimens were of poor 
quality. M. tuberculosis was detected in 60 (18.7%) good 
quality and 9 (9.6%) poor quality sputum specimens 
using Xpert. The overall error rate was similar in good 
(10.3%, 95%CI 7.3–14.3) and poor quality (9.6%, 
95%CI 4.7–17.8) sputum specimens. There was a sig-
nificantly higher positivity rate in good than in poor 
quality specimens (20.9%, 95%CI 16.4–26.2 vs. 10.6%, 
95%CI 5.3–19.6, P  0.05).
AFB smear microscopy
M. tuberculosis was detected in 10 (2.9%) AFB 
smear-negative specimens. Three (27.8%) of the speci-
mens were smear-positive but with no M. tuberculosis 
detected using Xpert. Xpert errors were detected in 34 
(10.6%) AFB smear-negative specimens and in 9 (9.6%) 
AFB smear-positive specimens.
The sensitivity and specificity of Xpert using mi-
croscopy as the gold standard was respectively 80.8% 
(95%CI 71.8–89.9) and 96.8% (95%CI 94.8–98.7). 
There was substantial agreement between microscopy 
and Xpert results (κ = 0.793).
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TABLE 1 Characteristics of sputum specimens tested using Xpert® MTB/RIF at three anti-tuberculosis treatment 






M. tuberculosis  
detected 
n (%)






 DMRL 164 (39.5) 32 (19.5) 113 (68.9) 19 (11.6)
 Lautoka 114 (27.5) 21 (18.4) 81 (71.1) 12 (10.5)
 Labasa 137 (33.0) 16 (11.7) 109 (79.6) 12 (8.8)
Sputum quality
 Good 318 (77.3) 60 (18.7) 227 (70.7) 34 (10.6)
 Poor 94 (22.7) 9 (9.6) 76 (80.9) 9 (9.6)
AFB smear result
 AFB 3+ 37 (8.9) 34 (91.9) 0 (0) 3 (8.1)
 AFB 2+ 8 (1.9) 6 (75.0) 0 (0) 2 (25.0)
 AFB 1+ 18 (4.3) 16 (88.9) 1 (5.6) 1 (5.6)
 Scanty not quantified 1 (0.2) 0 0 (0) 1 (100)
 Scanty and quantified 9 (2.2) 3 (33.3) 2 (22.2) 4 (44.4)
 Negative 342 (82.4) 10 (2.9) 300 (87.7) 32 (9.4)
Culture result
 Mycobacterium spp. isolated 55 (13.3) 41 (74.5) 3 (5.5) 11 (20.0)
 No growth 152 (36.6) 10 (6.6) 135 (88.8) 7 (4.6)
 Contaminated 10 (2.4) 1 (10.0) 8 (80) 1 (10.0)
 Not done 198 (47.7) 17 (8.6) 157 (79.3) 24 (12.1)
DMRL = Daulako Mycobacterium Reference Laboratory; AFB = acid-fast bacilli.
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TB culture
Of the 217 (52.3%) sputum specimens tested using both Xpert 
and culture, 10 (2.4%) were contaminated; 3 (5.5%) specimens 
were Xpert-negative but culture-positive. The sensitivity and spec-
ificity using culture as the gold standard were respectively 93.2% 
(95%CI 85.7–100.6) and 93.1% (95%CI 89.0–97.2). There was al-
most perfect agreement between culture and Xpert results (κ = 
0.818).
Errors
We detected a total of 43 (10.4%) errors. There were no significant 
differences in error rates in testing conducted in the three divi-
sions. The results of different error types are presented in Table 2. 
Error ‘5007’ (n = 10) and ‘no result’ (n = 11) were the most com-
mon errors recorded. DMRL recorded a high number of errors due 
to the large number of samples tested. The number of errors de-
tected at the Lautoka and Labasa Hospitals was the same (n = 12).
DISCUSSION
This is the first study in Fiji to evaluate the implementation of 
Xpert for TB diagnosis. Fiji does not currently perform routine 
drug susceptibility testing (DST) for M. tuberculosis isolates. In 
cases where DST is needed, culture isolates on Ogawa are sent to a 
reference laboratory in Australia for testing. To date, RMP resis-
tance has not been detected in any M. tuberculosis culture isolates 
from Fiji,6 and no RMP resistance was detected using Xpert during 
the study period.
One of the most significant logistical issues experienced during 
implementation was the overestimation of Xpert cartridge re-
quirements in the implementation phase, and the Xpert car-
tridges were obtained in a single shipment. In addition, only a 
small number of samples met the algorithm developed by the 
NTP for Xpert testing. Furthermore, as the purpose of the new test 
and the structure of the implementation phase were not commu-
nicated fully to the clinical staff in the hospitals in Fiji, except for 
those in the TB clinics, only a small number of requests came 
from doctors in the divisional hospitals, which have a large daily 
turnover of patients. Sputum samples were only submitted if the 
microscopy results were indeterminate. The end result was that 
about 30% of the 600 cartridges were discarded due to their short 
shelf-life. This was followed by a lapse of 7 months before the sec-
ond batch of test cartridges arrived. This suggests that the Fiji NTP 
needs both to revise its procurement guidelines to improve stock 
management for newly introduced tests and also to initiate train-
ing in Xpert and its value for medical officers, not only at the TB 
clinics but at all the other facilities in Fiji. In a similar study by 
Creswell et al. evaluating data from nine countries, cartridges 
were shipped in different batches to avoid waste.7 In addition, 
NTP guidelines for Xpert in the nine countries were more focused 
on detecting drug resistance than on active case finding.7
It is interesting to note that a high number of errors occurred 
in good quality sputum. We also documented high rates of M. tu-
berculosis in good quality sputum specimens. Use of good quality 
sputum for Xpert testing was also recommended in a study in 
Zimbabwe.8 Rectifying this error was therefore a priority for Fiji. A 
similar problem was observed in India after Xpert was decen-
tralised to a lower level of the health system.9 The majority of the 
failures in this case were caused by the high viscosity of good 
quality sputum samples. It was therefore recommended that spu-
tum specimens with high viscosity be incubated for an additional 
10 min before Xpert testing.9
Xpert correctly identified M. tuberculosis in 80% of the AFB 
smear-positive specimens, indicating that it reliably identifies the 
presence of M. tuberculosis in patients with a high bacterial load. 
In Fiji’s low-prevalence setting, the number of new Xpert-posi-
tive, smear-negative specimens was low (n = 3, 0.9%). In such a 
low-burden setting, the NTP needs to re-evaluate its stringent al-
gorithm for Xpert testing. In South Africa, the time to diagnosis 
increased by almost two-fold when Xpert (82%) was used for di-
agnosis followed by smear microscopy, culture and clinical obser-
vations (44%).10 In the multicentre study by Creswell et al., Xpert 
was used as a second test for smear-negative cases in the nine 
countries studied.7 It is important to note that Xpert can also be 
performed for highly suspected clinical cases.
Of the 10 cases that were AFB smear-negative but Xpert-posi-
tive for M. tuberculosis, 3 were new cases and 7 were follow-up pa-
tients who were on anti-tuberculosis medication at the time. The 
seven follow-up specimens were tested using Xpert only to check 
for any RMP resistance, as Xpert is not used to monitor 
treatment.
The almost perfect agreement between Xpert and culture is re-
TABLE 2 Number and type of error recorded after testing sputum specimens for the 











1018 1 (100.0) 0 (0) 0 (0) 1
2008 4 (44.4) 3 (33.3) 2 (22.3) 9
5006 1 (100.0) 0 (0) 0 (0) 1
5007 3 (30.0) 5 (50.0) 2 (20.0) 10
5011 3 (60.0) 1 (20.0) 1 (20.0) 5
Invalid 2 (33.3) 3 (33.3) 1 (16.4) 6
No result 5 (45.5) 0 (0) 6 (54.5) 11
 Total 19 12 12 43
* Xpert error results were defined according to the manufacturer’s specifications, as follows: 5006/5007/5008 = 
failure of probe check control; mainly associated with sputum viscosity and/or volume, incorrect filling of reaction 
tube or detection of probe integrity problem; 5011 = loss of tube pressure; 2008 = pressure exceeds maximum 
pressure acceptable, or failure of Xpert module, mostly caused by sample viscosity; 1018 = valve positioning error; 
invalid result = sample processing control, an inbuilt control, fails and the polymerase chain reaction was inhibited 
due to the presence of pus, blood or food particles; no result = insufficient data were collected because the test was 
stopped voluntarily or due to electrical failure.5
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assuring, as it suggests that culture is being performed relatively 
efficiently. Surprisingly, Xpert was unable to detect two AFB-posi-
tive smears as positive, although these were confirmed as positive 
on culture. The two cases were follow-up patients. This result was 
similar to a study in Uganda, where it was documented that the 
assay was unable to detect M. tuberculosis in 20.6% of children 
with culture-confirmed pulmonary TB.11 Similar results were 
found in a study performed in two hospitals in Cape Town, South 
Africa, where nearly a quarter of the children were M. tuberculo-
sis-negative using Xpert but positive using culture.12 A thorough 
clinical assessment is therefore important in introducing anti-tu-
berculosis treatment in Xpert-negative patients. Culture thus re-
mains the gold standard for the diagnosis of TB, as it has the abil-
ity to grow low concentrations of bacteria from sputum isolates, 
which can be used to perform DST and phenotyping.
Using Xpert, 43 (10.4%) errors were detected. The error code 
‘no result’ (n = 11, 26%) indicates a power failure; however, in 
this case no power failure was recorded in the three centres and 
all were using an uninterrupted power supply. Furthermore, al-
though Cepheid recommends that Xpert machines be calibrated 
after 2000 cycles or after 1 year,5 whichever comes first, calibra-
tion had still not been performed 1 year after installation. In the 
early programmatic implementation of Xpert in nine countries, 
the assay was repeated if it failed in the first run.7
As data from all Xpert tests were acquired from all the three 
centres in Fiji, this study is therefore representative of the nation-
wide implementation of Xpert. AFB microscopy and culture re-
sults were also extracted for comparison purposes, and the data 
collected were validated by cross-checking with the electronic 
data stored in Xpert.
The age of the samples could not be analysed due to unavail-
ability of the date of specimen collection. Although the dates re-
corded in the laboratory registers indicated when the sample had 
been received by the laboratory, they could not be taken as date 
of collection, as the samples were referred from different health 
facilities. We could not therefore determine whether the age of 
the sample affected Xpert results, and particularly the errors. 
However, in India, regional distribution, demographic profile and 
level of decentralisation were not related to test failures.9 Never-
theless, it is still recommended that all health facilities follow na-
tional guidelines and correctly identify the date of collection both 
in the request form and on the specimen container before send-
ing them to the test laboratory, both for Xpert testing and for cul-
ture, where the risk of contamination is high.
As Fiji will soon be introducing liquid culture on MGIT™ (BD, 
Sparks, MD, USA), further research with larger samples and com-
parisons of the four tests can be carried out.
CONCLUSION
This study shows a good correlation between Xpert and the two 
tests routinely used for TB diagnosis in Fiji. However, it also out-
lines a number of manageable obstacles to implementation. Fur-
ther evaluations of Xpert are required to re-evaluate the perfor-
mance of the test in detecting smear-negative, Xpert-positive 
cases over a longer time period. Because of logistical and sustain-
ability issues, Xpert cannot replace routine first-line diagnostic 
tests in Fiji.
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Contexte  :  Tous les tests Xpert® MTB/RIF réalisés dans les trois 
centres de traitement anti-tuberculeux aux Fidji entre juin 2012 et 
février 2013.
Objectifs  :  Déterminer 1) le nombre de tests Xpert réalisés dans 
chaque centre, 2) l’association entre la qualité des crachats et le 
résultat du test Xpert, 3) l’accord entre Xpert et la microscopie des 
crachats acido alcoolo résistant (AFB) et la culture, et 4) le taux 
d’erreurs.
Schéma  :  Revue rétrospective de dossiers.
Résultats  :  Un total de 415 tests Xpert a été réalisé pendant la 
période d’étude. Mycobacterium tuberculosis a été détecté dans 69 
(16.6%) échantillons. Aucune résistance à la rifampicine n’a été 
décelée. M. tuberculosis a été identifié dans 60 (18,7%) échantillons 
de crachats de bonne qualité. Un total de 43 (10,4%) erreurs sont 
survenues pendant la période d’étude. M. tuberculosis a été identifié 
dans 10 (2,9%) spécimens à frottis négatif. Il y a eu une concordance 
substantielle et presque parfaite entre les résultats du Xpert et ceux 
de la microscopie AFB (κ = 0,793) et de la culture (κ = 0,818), 
respectivement.
Conclusion  :  En dépit de la bonne corrélation entre Xpert et les deux 
autres tests mise en évidence dans l’étude, Xpert ne peut toujours 
pas remplacer les tests de diagnostic de routine utilisés en première 
intention aux Fidji, en raison de contraintes logistiques et de 
problèmes de pérennité. Il est nécessaire de réaliser une évaluation 
ultérieure de la performance de ce test sur une période plus longue 
afin de mesurer sa valeur diagnostique dans la détection de cas à 
frottis négatif, Xpert positif aux Fidji.  
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Marco de referencia: Todas las pruebas Xpert® MTB/RIF realizadas 
en los tres centros de atención de la tuberculosis (TB) de Fiji entre 
junio del 2012 y febrero del 2013.
Objetivos: Obtener la siguiente información: 1) el número de 
pruebas Xpert realizadas en cada centro; 2) la asociación entre la 
calidad de la muestra de esputo y el resultado de la prueba Xpert; 3) 
la concordancia de los resultados de esta prueba con la baciloscopia y 
el cultivo para Mycobacterium tuberculosis; y 4) las tasas de error de la 
prueba.
Método: Fue este un estudio retrospectivo a partir de las historias 
clínicas.
Resultados: Durante el período del estudio se practicaron 415 
pruebas Xpert. Esta prueba aportó un resultado positivo para M. 
tuberculosis en 69 muestras de esputo (16,6%). No se encontró 
resistencia a rifampicina. Se detectó M. tuberculosis en 60 de muestras 
de esputo de buena calidad (18,7%). Se registraron 43 resultados de 
error de la prueba durante el período estudiado (10,4%). La prueba 
detectó M. tuberculosis en 10 muestras con baciloscopia negativa 
(2,9%). La concordancia de los resultados de la prueba Xpert con la 
baciloscopia del esputo fue notable (κ = 0,793) y casi perfecta con los 
resultados del cultivo (κ = 0,818).
Conclusión: Si bien en el presente estudio la prueba Xpert exhibió 
una buena correlación con los métodos de referencia, todavía no 
puede remplazar las pruebas sistemáticas de elección en el 
diagnóstico de la TB en Fiji por razones operativas y de sostenibilidad. 
Es necesario realizar nuevos estudios de rendimiento diagnóstico 
durante un período más prolongado, a fin de estimar su utilidad 
diagnóstica en los casos que presentan una baciloscopia negativa y 
una prueba Xpert positiva en Fiji.  
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